CA2730789A1 - Treatment of inflammatory bowel diseases with mammal beta defensins - Google Patents

Treatment of inflammatory bowel diseases with mammal beta defensins Download PDF

Info

Publication number
CA2730789A1
CA2730789A1 CA2730789A CA2730789A CA2730789A1 CA 2730789 A1 CA2730789 A1 CA 2730789A1 CA 2730789 A CA2730789 A CA 2730789A CA 2730789 A CA2730789 A CA 2730789A CA 2730789 A1 CA2730789 A1 CA 2730789A1
Authority
CA
Canada
Prior art keywords
beta defensin
mammal
seq
human beta
body weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2730789A
Other languages
English (en)
French (fr)
Inventor
Tanja Maria Rosenkilde Kjaer
Thomas Kruse
Per Holse Mygind
Karoline Sidelmann Brinch
Soeren Kjaerulff
Birgitte Andersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes Biopharma DK AS
Original Assignee
Novozymes Adenium Biotech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41530820&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2730789(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novozymes Adenium Biotech AS filed Critical Novozymes Adenium Biotech AS
Priority to CA2750727A priority Critical patent/CA2750727A1/en
Publication of CA2730789A1 publication Critical patent/CA2730789A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2730789A 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with mammal beta defensins Abandoned CA2730789A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2750727A CA2750727A1 (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with mammal beta defensins

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP08160761.6 2008-07-18
EP08160761 2008-07-18
EP08162486 2008-08-15
EP08162486.8 2008-08-15
EP08163614 2008-09-03
EP08163614.4 2008-09-03
PCT/EP2009/059253 WO2010007166A2 (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with mammal beta defensins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2750727A Division CA2750727A1 (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with mammal beta defensins

Publications (1)

Publication Number Publication Date
CA2730789A1 true CA2730789A1 (en) 2010-01-21

Family

ID=41530820

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2750727A Abandoned CA2750727A1 (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with mammal beta defensins
CA2730789A Abandoned CA2730789A1 (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with mammal beta defensins

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2750727A Abandoned CA2750727A1 (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with mammal beta defensins

Country Status (20)

Country Link
US (4) US8232242B2 (ko)
EP (2) EP2399600A1 (ko)
JP (2) JP2011528333A (ko)
KR (1) KR20110092325A (ko)
CN (2) CN102247591A (ko)
AP (2) AP2011005538A0 (ko)
AR (2) AR072032A1 (ko)
AU (1) AU2009272681A1 (ko)
BR (2) BRPI0924481A2 (ko)
CA (2) CA2750727A1 (ko)
CL (1) CL2011000099A1 (ko)
EA (2) EA201100910A1 (ko)
IL (2) IL210715A0 (ko)
MX (1) MX2011000568A (ko)
NZ (2) NZ590468A (ko)
PH (1) PH12012501542A1 (ko)
SG (1) SG172709A1 (ko)
TW (2) TW201004640A (ko)
WO (1) WO2010007166A2 (ko)
ZA (1) ZA201100461B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2399600A1 (en) 2008-07-18 2011-12-28 Novozymes Adenium Biotech A/S Treatment of inflammatory bowel diseases with mammal beta defensins
CA2730666A1 (en) * 2008-07-18 2010-01-21 Novozymes Adenium Biotech A/S Treatment of rheumatoid arthritis with mammal beta defensins
AR072524A1 (es) * 2008-07-18 2010-09-01 Novozymes As Tratamiento de enfermedades inflamatorias con beta defensinas de mamiferos
KR101329774B1 (ko) * 2010-06-16 2013-11-15 주식회사 나이벡 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물
NZ732118A (en) 2011-04-15 2018-11-30 Marine Polymer Tech Inc Treatment of disease with poly-n-acetylglucosamine nanofibers
WO2013007596A2 (en) 2011-07-08 2013-01-17 Novozymes A/S Oral treatment of inflammatory bowel disease
WO2013026794A1 (en) 2011-08-19 2013-02-28 Novozymes Novel immunomodulatory peptide
US10257564B2 (en) * 2013-01-24 2019-04-09 Saturn Licensing Llc Distributed non-real-time content
CN104628864B (zh) * 2013-11-14 2020-04-10 中国医学科学院医药生物技术研究所 一种抗肿瘤融合蛋白EL-defensin、其编码基因和用途
JP2019514908A (ja) 2016-04-29 2019-06-06 ディフェンシン セラピューティクス エーピーエス 肝臓、胆管および膵臓の障害の治療
CA3045079A1 (en) 2016-12-13 2018-06-21 Defensin Therapeutics Aps Methods for treating inflammatory conditions of the lungs
CN111556759A (zh) 2017-11-10 2020-08-18 防御素治疗学公司 早产儿中的粘膜防御和肠道/肺功能的成熟化
MX2020005370A (es) 2017-11-24 2020-10-19 Defensin Therapeutics Aps Prevencion y tratamiento de enfermedad de injerto contra hospedero con defensinas.
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
CN113684162B (zh) * 2021-06-03 2024-02-27 江南大学 一种表达小鼠防御素mBD14基因的重组植物乳杆菌及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6576755B1 (en) * 1997-09-10 2003-06-10 Zymogenetics, Inc. Beta-defensins
DE19957043A1 (de) * 1999-11-26 2001-06-07 Forssmann Wolf Georg Neue Defensine
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
FR2841556B1 (fr) 2002-07-01 2007-07-20 Centre Nat Rech Scient Peptides ayant des proprietes antimicrobiennes et les compositions les contenant notamment pour la conservation des aliments
CA2508273A1 (en) 2002-12-19 2004-07-08 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
US20070207209A1 (en) 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
GB0514482D0 (en) * 2005-07-14 2005-08-17 Ares Trading Sa Protein
WO2007081486A2 (en) * 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
WO2007087557A2 (en) 2006-01-24 2007-08-02 University Of Maryland Biotechnology Institute Surface-layer protein coated microspheres and uses thereof
CA2699163A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
AR072524A1 (es) 2008-07-18 2010-09-01 Novozymes As Tratamiento de enfermedades inflamatorias con beta defensinas de mamiferos
CA2730666A1 (en) 2008-07-18 2010-01-21 Novozymes Adenium Biotech A/S Treatment of rheumatoid arthritis with mammal beta defensins
EP2399600A1 (en) 2008-07-18 2011-12-28 Novozymes Adenium Biotech A/S Treatment of inflammatory bowel diseases with mammal beta defensins
WO2013007596A2 (en) 2011-07-08 2013-01-17 Novozymes A/S Oral treatment of inflammatory bowel disease
WO2013026794A1 (en) 2011-08-19 2013-02-28 Novozymes Novel immunomodulatory peptide

Also Published As

Publication number Publication date
BRPI0915973A2 (pt) 2013-05-07
AR081948A2 (es) 2012-10-31
JP2011528333A (ja) 2011-11-17
US20110251139A1 (en) 2011-10-13
ZA201100461B (en) 2014-03-26
KR20110092325A (ko) 2011-08-17
AR072032A1 (es) 2010-07-28
IL210715A0 (en) 2011-03-31
EP2399600A1 (en) 2011-12-28
EA201100910A1 (ru) 2012-05-30
US8232242B2 (en) 2012-07-31
JP2011225596A (ja) 2011-11-10
TW201004640A (en) 2010-02-01
CA2750727A1 (en) 2010-01-21
CL2011000099A1 (es) 2011-10-07
IL213680A0 (en) 2011-07-31
SG172709A1 (en) 2011-07-28
CN102247591A (zh) 2011-11-23
US20120309678A1 (en) 2012-12-06
US20100016230A1 (en) 2010-01-21
CN102159233A (zh) 2011-08-17
US8802621B2 (en) 2014-08-12
PH12012501542A1 (en) 2015-11-09
NZ593653A (en) 2012-09-28
BRPI0924481A2 (pt) 2015-08-11
WO2010007166A3 (en) 2010-06-03
EP2320930A2 (en) 2011-05-18
AP2011005538A0 (en) 2011-02-28
EA201170219A1 (ru) 2011-08-30
MX2011000568A (es) 2011-02-23
AU2009272681A1 (en) 2010-01-21
TW201138810A (en) 2011-11-16
NZ590468A (en) 2012-06-29
WO2010007166A2 (en) 2010-01-21
US9279010B2 (en) 2016-03-08
AP2011005755A0 (en) 2011-06-30
US20140135258A1 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
CA2730789A1 (en) Treatment of inflammatory bowel diseases with mammal beta defensins
JP2011528333A5 (ko)
US10335455B2 (en) Method for prevention or treatment of intractable inflammatory bowel disease
JP2011225596A5 (ko)
WO2007136518A3 (en) Treatment of autoimmune disorders
US9359405B2 (en) Antagonists of the interleukin-1 receptor
WO2012142320A3 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
IL273913B2 (en) Tripeptidyl peptidase-1 preparations and methods for treating neuronal ceroid liposuction disease
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
JP2016516016A5 (ko)
JP2011507855A5 (ko)
JP2011507861A5 (ko)
JP2014520893A5 (ko)
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
JP2011528334A5 (ko)
WO2007096396A3 (en) Methods for treating autoimmune or demyelinating diseases
KR20210042417A (ko) 경구 점막염 치료에 사용하기 위한 신규한 펩티드 및 유사체
WO2013059879A1 (en) Compositions and methods for the treatment of fibrosis and fibrotic diseases
CN106366166A (zh) 脑源性神经营养因子促进剂多肽及应用
CA2797974A1 (en) Selective integrin inhibitors
US9616100B2 (en) Methods of use of HSP70 for increased performance or treatment of HSP70 related disorders
JP2014523437A (ja) 癌の予防および治療における効力のある薬剤としての新規亜鉛フィンガー様ペプチド組成物
CA3097989A1 (en) Methods for improving frailty and aging
Emery et al. Promoting neuronal tolerance of diabetic stress: modulating molecular chaperones

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140717